biotechnology

Companies present solutions to tomorrow’s problems today through biotechnology at Alimentaria trade show

Researchers at the Hospital Germans Trias in Badalona (Greater Barcelona) have taken an important step toward creating a vaccine for Type 1 diabetes, which currently has no cure. The discovery, published in the scientific journal 'Plos One', consists of the preparation of nanoparticles in the laboratory that, once introduced into the body, slow down the destruction of beta cells (whose primary function is to store and release insulin). With Type 1 diabetes, the body’s immune system attacks these insulin-producing cells located in the pancreas and destroys them. Currently, to combat the disease, patients must take insulin injections. In recent years, Catalonia has become a global hub for biomedical investigation, developing cutting-edge research initiatives and participating in leading international projects. With just 0.1% of the world’s population, Catalonia accounts for nearly 1% of global scientific production and attracts 2.2% of European competitive funds and 3.5% of European Research Council (ERC) grants.

A new computational method allows the detection, within just a few hours, of the genetic alterations responsible for the formation and progression of cancer tumours. This new method manages to accurately identify almost all types of genetic changes of cancer cells in a simple, quick and precise way. It is also able to identify large-scale chromosome rearrangements, which had been difficult to be detect until this breakthrough. The new method, called SMUFIN, has been developed by the Barcelona Supercomputing Centre and the ICREA (Catalan Institution of Research and Advanced Studies), in collaboration with research groups from Barcelona, Oviedo and Heidelberg. This progress has been published by the prestigious journal 'Nature Biotechnology' and represents a significant step forward towards the personalised treatment of cancer and other illnesses.

The Catalan Institute of Nanoscience and Nanotechnology (ICN2) has set up its new headquarters at the Universitat Autònoma de Barcelona (UAB) campus. The new faculties are located in a 6,000 square meter building with 40 laboratories, where scientific projects will be developed in different areas, from biomedicine to the development of everyday products such as paint or detergents.. This project is funded by both the Catalan and Spanish Governments and aims to make the centre a flagship in the European scientific field.

Christian Brander is a researcher at the IrsiCaixa AIDS Research Institute and Scientific Director of HIVACAT, the programme for the development of a HIV vaccine. He graduated from the University of Bern in 1994 with a PhD in Immunology and has spent 13 years at Harvard University focusing on cellular immunity to viral infections.

Between the 11th and 13th of March, Barcelona will host the spring meeting of Bio-Europe, the continent’s largest partnering conference of the global biotechnology industry, for the second time. 1,300 biomedical companies will participate in the event, with more than 2,000 delegates and executives. 60 out of the 100 Spanish companies attending are from Catalonia. In the last decade, Catalonia, particularly the Greater Barcelona area, has become the most important centre in Southern Europe within the biomedical field and one of the main centres internationally. Barcelona’s Deputy Mayor for Economic Affairs, Sònia Recasens, praised the importance of the event as it boosts those “added-value sectors that are strategic for the city’s economic growth”.

The President of the Catalan Government, Artur Mas, travelled to Massachusetts and New York to promote Catalan businesses and present Catalonia as one of the main biotechnological clusters and tourist destinations in Europe. In addition, Ernst & Young presented their report on life sciences companies and research centres in Catalonia, which indicates that almost 30% of this sector’s turnover in Spain comes from Catalan businesses.

The results of the research will be helpful to expand the knowledge on diseases related to the process of protein aggregation. Discovery of this might lead to the early detection of Alzheimer ’s disease. The research has found a way to precisely measure the effects that protein aggregation has on cell aging.